In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug

In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug

The FDA approved Ionis Pharmaceuticals’ Dawnzera for preventing swelling attacks caused by the rare disease hereditary angioedema. A Takeda Pharmaceutical product dominates this market, but Ionis has clinical data showing patients had better outcomes after switching to Dawnzera from Takeda’s drug and other currently available HAE medications. The post In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class…

Ionis brings long-acting treatment option to HAE patients

Ionis gets FDA nod for its HAE attack prophylactic treatment Dawnzera, offering less frequent dosing than its rivals

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

CARLSBAD, Calif.--(BUSINESS WIRE)--Aug 21, 2025-

FDA approves first RNA-targeted therapy for hereditary angioedema

In recent studies, donidalorsen (DAWNZERA) has demonstrated durable efficacy and long-term disease control.

FDA Approves Donidalorsen as First RNA-Targeted Prophylactic Treatment for Hereditary Angioedema

The FDA approves donidalorsen, the first RNA-targeted therapy for hereditary angioedema, offering significant attack reduction and convenient administration.

Pioneering RNA-Targeted Therapy FDA Greenlights DAWNZERA for Hereditary Angioedema,

'U.S. FDA Approves DAWNZERA as First RNA-Targeted Treatment for Hereditary Angioedema' In a groundbreaking development for the treatment of hereditary angioedema (HAE), Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA (donidalorsen). This approval marks a significant milestone as DAWNZERA becomes the first and only RNA-targeted prophylactic treatment available for HAE…